sglt vs glp 1 Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism Renal outcomes of SGLT2 inhibitors

doi: 10.3389/fnagi.2022.1059017 Received 30 September 2022 Accepted 12 December 2022 Published 06 January 2023 Volume 14 - 2022 Edited by Panteleimon Giannakopoulos, Universit de Genve, Switzerland Reviewed by Aarti Mishra, AbbVie, United States

PMCID: PMC1975347

For now, Lilly remains one of Wall Streets highest-conviction healthcare growth stories

Fr eine offene Diskussion behalten wir uns vor, jeden Kommentar zu lschen, der nicht direkt auf das Thema abzielt oder nur den Zweck hat, Leser oder Autoren herabzuwrdigen

Speak with a licensed clinician before starting any peptide protocol, and review the regulatory status section before assuming legal availability